Author: Amara Maple

The Endocrine Society has officially announced the commencement of its Rare Endocrine Disease (RED) Fellows Program, a comprehensive educational initiative designed to fortify the expertise of early-career physicians. This strategic series is engineered to provide participants with the advanced knowledge and practical clinical skills essential for improving health outcomes for patients navigating the complexities of…

In a landmark development for the treatment of type 2 diabetes and metabolic health, Eli Lilly and Company has announced that its investigational once-daily oral medication, orforglipron, successfully met all primary and secondary endpoints in two pivotal Phase 3 clinical trials. The trials, known as ACHIEVE-2 and ACHIEVE-5, represent a significant milestone in the pharmaceutical…

The study provides a detailed roadmap of how semaglutide interacts with the tumor microenvironment (TME), specifically targeting immune cells known as tumor-associated macrophages (TAMs). By "reprogramming" these cells from a state that supports tumor growth to one that actively attacks it, the drug demonstrates an unexpected anti-oncogenic potential. As semaglutide continues its meteoric rise as…

In observance of American Heart Month this February, the medical community is intensifying its focus on the intersection of metabolic health and cardiovascular disease, the leading cause of mortality globally. Recent breakthroughs in pharmacotherapy, specifically involving glucagon-like peptide-1 receptor agonists (GLP-1RAs) and emerging multi-receptor agonists, have fundamentally altered the treatment landscape for obesity and its…

As the pharmaceutical landscape undergoes a seismic shift driven by the proliferation of anti-obesity and glucose-lowering medications, the medical community is pivoting from a focus on weight loss to a rigorous examination of long-term systemic benefits. In late 2025, two landmark studies provided critical clarity on the cardiovascular implications of glucagon-like peptide-1 receptor agonists (GLP-1RAs)…

In a strategic move to address the growing financial and professional challenges facing the global scientific community, the Endocrine Society has unveiled a comprehensive suite of initiatives designed to support endocrine researchers at every stage of their careers. As the premier global organization representing professionals in the field of endocrinology, the Society’s latest efforts are…

The field of neuroendocrinology is currently undergoing a transformative shift as researchers move beyond traditional observational studies toward sophisticated molecular modeling and personalized medicine. At the forefront of this evolution in South America is Maria Andrea Camilletti, PhD, an assistant researcher at the Laboratorio de Investigaciones Aplicadas en Neurociencias (LIAN), within the Instituto de Neurociencias…

The pharmaceutical landscape is currently witnessing a paradigm shift as glucagon-like peptide-1 receptor agonists (GLP-1RAs), once specialized tools for glycemic control, emerge as multi-purpose therapeutic agents with the potential to reshape modern medicine. While these medications have been utilized for decades to manage type 2 diabetes and short bowel syndrome, their recent explosion in popularity—driven…

The Endocrine Society has officially announced that Samuel Klein, MD, the William H. Danforth Professor of Medicine and Nutritional Science at Washington University School of Medicine in St. Louis, is the 2026 recipient of the Outstanding Clinical Investigator Laureate Award. This prestigious recognition honors a career spanning more than three decades, during which Dr. Klein…

The medical landscape is currently navigating a transformative era defined by the meteoric rise of glucagon-like peptide-1 receptor agonists, commonly known as GLP-1RAs. Once primarily utilized as a secondary treatment for Type 2 diabetes, this class of pharmaceuticals—including household names like semaglutide and tirzepatide—has transitioned into a cultural and clinical zeitgeist. The influence of these…